WE COMBINE SCIENCE WITH NEEDS OF THE WORLD OF PHARMACY
We want to change medicines to make them better – we are open to challenges
Amorphis Pharma Development Sp. z o.o. was created from a combination of knowledge and achievements of outstanding scientists in the field of molecular physics represented by Professor Marian Paluch and PhD. Eng. Justyna Knapik – Kowalczuk, with substantive support and scientific and research base represented by a spin-off company of the University of Silesia (SPIN-US), with the involvement of business practitioners with experience in the pharmaceutical field (HMC), as well as specialists in the drug development and investment fund (InnoVenture ). The company was established in response to the identified area of the pharmaceutical market needs which is the low solubility of many pharmaceutically active substances.
Solubility has a direct impact on the bioavailability of the pharmaceutical and – as a result – the effectiveness of the therapy. The problem of low solubility of active substances on a large scale affects both those used already in drugs on the market and those still in development.
That is why our company was founded with the support of many years of scientific and business experience and many exceptional achievements. The main goal is creating drugs with better properties compared to the originals.
We create products in the Added Value Medicines segment
Amorphis Pharma Development is mastering its specialization in the amorphization and stabilization of pharmaceutical active substances to create drugs from the Added Value Medicines segment, i.e. those that have better characteristics compared to the originals.
One of them is the multiple improvement of effectiveness. This means that a smaller amount of active substance in amorphous form may have the same therapeutic effect as a larger but crystalline dose of the same substance. Thus, drugs in a stable amorphous form may have lower doses, which means an improvement in the comfort of therapy for patients (e.g. smaller tablet, less effect on the gastrointestinal tract, no need to use with food, less frequent dosing, and additionally less negative impact on the environment);
We develop improved generic substances, and – together with our partners – we co- develop innovative substances using methods developed by the Amorphis research team.
The project is implemented with the financial support of the European Union from the Intelligent Development Operational Program 2014-2020 Action 1.3: R&D works financed with the participation of capital funds. Project “Amorphous Drugs”. Value of support: 1 071 149,95 PLN.
We create products in the Added Value Medicines segment
Amorphis Pharma Development is mastering its specialization in the amorphization and stabilization of pharmaceutical active substances to create drugs from the Added Value Medicines segment, i.e. those that have better characteristics compared to the originals.
One of them is the multiple improvement of effectiveness. This means that a smaller amount of active substance in amorphous form may have the same therapeutic effect as a larger but crystalline dose of the same substance. Thus, drugs in a stable amorphous form may have lower doses, which means an improvement in the comfort of therapy for patients (e.g. smaller tablet, less effect on the gastrointestinal tract, no need to use with food, less frequent dosing, and additionally less negative impact on the environment);
We develop improved generic substances, and – together with our partners – we co- develop innovative substances using methods developed by the Amorphis research team.
The project is implemented with the financial support of the European Union from the Intelligent Development Operational Program 2014-2020 Action 1.3: R&D works financed with the participation of capital funds. Project “Amorphous Drugs”. Value of support: 1 071 149,95 PLN.